A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization), CT. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Performance of Spectral CT in Evaluating Treatment Response After Transarterial Chemoembolization for Hepatocellular Carcinoma: The SpecTRAIL Study
Overview
By comparing the diagnostic accuracy of spectral CT and conventional CT in evaluating treatment response efficacy after TACE, this study aims to investigate the diagnostic performance of spectral CT in assessing treatment response following TACE for hepatocellular carcinoma.
Primary outcome measures
- Diagnostic accuracy of spectral CT in identifying nonviable HCC lesions. [Time frame: From enrollment to the completion of the 1-year follow-up]
- Diagnostic Performance of Spectral CT for Residual Viable Hepatocellular Carcinoma After TACE. [Time frame: From enrollment to the completion of the 1-year follow-up.]
Eligibility criteria
Inclusion criteria
- age 18-75 years;
- diagnosis of HCC based on pathological findings or accepted clinical and imaging criteria;
- Barcelona Clinic Liver Cancer (BCLC) stage A or B;
- prior treatment with TACE;
- undergoing contrast-enhanced spectral CT at 4-8 weeks after TACE;
- undergoing either liver resection within 1 week after contrast-enhanced spectral CT (surgical cohort) or undergoing hepatic digital subtraction angiography (DSA) or contrast-enhanced MRI within 1 week after contrast-enhanced spectral CT (non-surgical cohort);
- informed consent.
Exclusion criteria
- contraindications to contrast-enhanced CT or MRI;
- presence of extrahepatic malignancy;
- poor image quality or incomplete clinical data;
- lack of regular CT or MRI follow-up in non-surgical cohort;
- withdrawal from the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Zhongda Hospital Southeast University — Nanjing
Identifiers
NCT: NCT07351669 · 2025ZDSYLL494-P01